文献速递血栓与止血

针对组织因子途径抑制物Kunitz-1结构域的单克隆抗体可阻止其对Xa因子和VIIa因子的抑制

Factor Xa and VIIa inhibition by tissue factor pathway inhibitor is prevented by a monoclonal antibody to its Kunitz-1 domain.
PubMed 文献 · J Thromb Haemost · 2018-04-06

本研究制备了靶向组织因子途径抑制物(TFPI)K1结构域的单克隆抗体mAb2F22,通过表面等离子共振和X射线晶体学分析其结合表位,并在缓冲液和血浆体系中检测其对TFPI抑制功能的影响。结果显示mAb2F22特异性结合K1结构域(KD约1 nm)而不结合K2,可中和TFPI对TF/FVIIa和FXa活性的抑制,并在血友病A样血浆和全血中恢复 clot 形成。

要点

  • mAb2F22仅结合TFPI的K1结构域(KD约1 nm),不结合K2结构域。
  • mAb2F22可中和TFPI对TF/FVIIa和FXa活性的抑制。
  • 在血友病A样血浆和全血中,mAb2F22恢复 clot 形成。

核心结论

  • mAb2F22通过结合TFPI的K1结构域,阻断TFPI对FVIIa和FXa活性的抑制,逆转TFPI对TF/FVIIa诱导的凝血反馈抑制,并在FVIII中和的人血浆和全血中恢复 clot 形成。

研究设计与样本

  • 制备针对TFPI N端片段TFPI(1-79)的单克隆抗体mAb2F22,通过表面等离子共振分析结合特性,表达Fab片段Fab2F22并用X射线晶体学解析其与TFPI(1-79)的复合物结构,在缓冲液和血浆体系中检测mAb2F22对TFPI抑制功能的影响。

主要发现

  • mAb2F22仅结合TFPI的K1结构域(KD约1 nm),不结合K2结构域。
  • Fab2F22/TFPI(1-79)晶体结构显示表位位于K1结构域,包括该结构域上游的七个残基。
  • mAb2F22中和了TFPI对TF/FVIIa酰胺水解活性的抑制,尽管K1上的结合表位不包含P1残基。
  • mAb2F22结合K1阻断了TFPI对FXa酰胺水解活性的抑制,并在血友病A样人血浆和全血中使止血正常化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials Activated FVII (FVIIa) and FX (FXa) are inhibited by tissue factor pathway inhibitor (TFPI). A monoclonal antibody, mAb2F22, was raised against the N-terminal fragment of TFPI (1-79). mAb2F22 bound exclusively to the K1 domain of TFPI (KD ∼1 nm) and not to the K2 domain. mAb2F22 interfered with inhibition of both FVIIa and FXa activities and restored clot formation. SUMMARY: Background Initiation of coagulation is induced by binding of activated factor VII (FVIIa) to tissue factor (TF) and activation of factor X (FX) in a process regulated by tissue factor pathway inhibitor (TFPI). TFPI contains three Kunitz-type protease inhibitor domains (K1-K3), of which K1 and K2 block the active sites of FVIIa and FXa, respectively. Objective To produce a monoclonal antibody (mAb) directed towards K1, to characterize the binding epitope, and to study its effect on TFPI inhibition. Methods A monoclonal antibody, mAb2F22, was raised against the N-terminal TFPI(1-79) fragment. Binding data were obtained by surface plasmon resonance analysis. The Fab-fragment of mAb2F22, Fab2F22, was expressed and the structure of its complex with TFPI(1-79) determined by X-ray crystallography. Effects of mAb2F22 on TFPI inhibition were measured in buffer- and plasma-based systems. Results mAb2F22 bound exclusively to K1 of TFPI (KD ~1 nm) and not to K2. The crystal structure of Fab2F22/TFPI (1-79) mapped an epitope on K1 including seven residues upstream of the domain. TFPI inhibition of TF/FVIIa amidolytic activity was neutralized by mAb2F22, although the binding epitope on K1 did not include the P1 residue. Binding of mAb2F22 to K1 blocked TFPI inhibition of the FXa amidolytic activity and normalized hemostasis in hemophilia human A-like plasma and whole blood. Conclusion mAb2F22 blocked TFPI inhibition of both FVIIa and FXa activities and mapped a FXa exosite for binding to K1. It reversed TFPI feedback inhibition of TF/FVIIa-induced coagulation and restored clot formation in FVIII-neutralized human plasma and blood.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Augustsson C, Svensson A, Kjaer B, et al. Factor Xa and VIIa inhibition by tissue factor pathway inhibitor is prevented by a monoclonal antibody to its Kunitz-1 domain. J Thromb Haemost. 2018. PMID: 29532595. doi:10.1111/jth.14000

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。